Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Research Report 2025

Publication ID:

PB501256000

Publication Date:

January 15, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Chicken embryos were inoculated with chicken embryos mixed with chicken newcastle virus ii strains and chicken pox virus weak strains, chicken infectious bronchitis virus H120 strains were inoculated with chicken embryos alone, chicken embryo solution and villurionic allantouria membrane were harvested, homogenized in a certain proportion, stabilizer was added, and dried by freezing vacuum.
Global demand for poultry products such as chicken and eggs continues to grow owing to factors such as population growth, increasing disposable income, and changing dietary preferences. This increased demand requires healthier and more efficient poultry farming methods, including vaccinations to prevent disease.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine.
The Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Box) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Boehringer Ingelheim
Pulike
Luoyang Huizhong Biotechnology Co., Ltd.
Segment by Type
Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Live
Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Inactivated
Segment by Application
Veterinary Drug
Scientific Research
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Overview
1.1 Product Definition
1.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine by Type
1.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Live
1.2.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Inactivated
1.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine by Application
1.3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Veterinary Drug
1.3.3 Scientific Research
1.4 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue 2020-2031
1.4.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales 2020-2031
1.4.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Competition by Manufacturers
2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Date of Enter into This Industry
2.8 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Competitive Situation and Trends
2.8.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Players 麻豆原创 Share by Revenue
2.8.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Scenario by Region
3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region: 2020-2031
3.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region: 2020-2025
3.2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region: 2026-2031
3.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region: 2020-2031
3.3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region: 2020-2025
3.3.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region: 2026-2031
3.4 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Facts & Figures by Country
3.4.1 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2020-2031)
3.4.3 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2020-2031)
3.5.3 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Type (2020-2031)
4.1.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Type (2020-2025)
4.1.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Type (2026-2031)
4.1.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Type (2020-2031)
4.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Type (2020-2025)
4.2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Type (2026-2031)
4.2.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2020-2031)
5.1.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2020-2025)
5.1.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2026-2031)
5.1.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2020-2031)
5.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2020-2025)
5.2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2026-2031)
5.2.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Boehringer Ingelheim Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Pulike
6.2.1 Pulike Company Information
6.2.2 Pulike Description and Business Overview
6.2.3 Pulike Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pulike Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Portfolio
6.2.5 Pulike Recent Developments/Updates
6.3 Luoyang Huizhong Biotechnology Co., Ltd.
6.3.1 Luoyang Huizhong Biotechnology Co., Ltd. Company Information
6.3.2 Luoyang Huizhong Biotechnology Co., Ltd. Description and Business Overview
6.3.3 Luoyang Huizhong Biotechnology Co., Ltd. Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Luoyang Huizhong Biotechnology Co., Ltd. Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Portfolio
6.3.5 Luoyang Huizhong Biotechnology Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Industry Chain Analysis
7.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Production Mode & Process Analysis
7.4 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales and 麻豆原创ing
7.4.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Channels
7.4.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Distributors
7.5 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Customer Analysis
8 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Dynamics
8.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Industry Trends
8.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Drivers
8.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Challenges
8.4 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Boehringer Ingelheim
Pulike
Luoyang Huizhong Biotechnology Co., Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.